Physician profile
Cyrus Hamidi
NPI 1134102775
$6,371.31
in general payments reported to CMS, 2019-2025
33 companies · $1,197 in 2025
The $1,197 reported for 2025 was more than what 92% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $595 · 2020: $514 · 2021: $1,126 · 2022: $676 · 2023: $1,186 · 2024: $1,077 · 2025: $1,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,460.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,159.13 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $934.56 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $891.67 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $860.05 | 2019-2025 | Rybelsus, Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $391.57 | 2019-2024 | Takhzyro, Trintellix |
| Glaxosmithkline, LLC. | $363.83 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Exact Sciences Corporation | $340.31 | 2023-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $244.66 | 2023-2025 | Gemtesa |
| Pfizer INC. | $190.74 | 2023-2025 | |
| Amarin Pharma, INC. | $133.88 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $92.83 | 2021-2023 | Qelbree |
| Phathom Pharmaceuticals, INC. | $91.81 | 2024-2025 | Voquezna |
| Amgen INC. | $87.43 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.61 | 2022-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $55.12 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $51.97 | 2023-2024 | Rexulti |
| Harmony Biosciences LLC | $41.92 | 2022 | |
| Xeris Pharmaceuticals, INC. | $38.53 | 2022-2025 | Gvoke Hypopen |
| Astellas Pharma US INC | $33.80 | 2019-2024 | Veozah |
| Allergan, INC. | $33.60 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $31.20 | 2025 | Spravato |
| Biohaven Pharmaceutical Holding Company Ltd. | $27.32 | 2022 | |
| Madrigal Pharmaceuticals | $24.59 | 2025 | Rezdiffra |
| Biohaven Pharmaceuticals, INC. | $24.19 | 2021 | |
| Bausch Health US, LLC | $23.85 | 2023 | Wellbutrin |
| Almatica Pharma LLC | $21.54 | 2023 | Gralise |
| Watermark Medical, INC. | $20.27 | 2024 | |
| Abbott Laboratories | $19.93 | 2023 | Freestyle Libre 3 |
| Paratek Pharmaceuticals, INC. | $19.61 | 2024 | Nuzyra |
| Dynavax Technologies Corporation | $17.12 | 2025 | Heplisav-B |
| Idorsia Pharmaceuticals US INC | $16.36 | 2022 | |
| Inspire Medical Systems, INC. | $15.65 | 2025 | Inspire |
| Horizon Therapeutics Plc | $14.66 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cyrus Hamidi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.